BTI’s Power Ranking 2016 recognized Schiff Hardin in its top category—Clientopia®—for the firm’s work on behalf of the pharmaceutical industry. Only 10 firms received this honor, and Schiff Hardin is one of only two honored firms that focuses on IP work for generics.
“BTI’s ranking is a great honor because it is based on client feedback, which is the best indicator of how our team is performing,” said Sailesh K. Patel, co-leader of the firm’s Intellectual Property and Hatch-Waxman and Biosimilars Groups. “I’m proud to work alongside such dedicated, hardworking colleagues to tackle our pharmaceutical clients’ most complex challenges.”
BTI defines Clientopia as “the ideal state of a client relationship.” The ranking is based on interviews with more than 320 general counsels, chief legal officers, and other senior decision makers. By earning this ranking, Schiff Hardin has “the foresight to know where the industry is going and what pharmaceutical companies interested in growth should know to get there.”